Osimertinib versus osimertinib plus chemotherapy for non–small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial-Reference-Cited by-同舟云学术

Osimertinib versus osimertinib plus chemotherapy for non–small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial

Published:2021-05 Issue: Volume:149 Page:14-22
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Tanaka Kentaro,Asahina Hajime^ORCID,Kishimoto Junji,Miyata Yoshihiro,Uchida Takahiro,Watanabe Kana,Hamai Kosuke^ORCID,Harada Taishi,Tsubata Yukari^ORCID,Sugawara Shunichi^ORCID,Kobayashi Kunihiko,Sugio Kenji,Oizumi Satoshi,Okamoto Isamu

Funder

AstraZeneca

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference19 articles.

1. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer;Cross;Canc Discov,2014

2. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer;Janne;N Engl J Med,2015

3. Osimertinib or platinum-pemetrexed in EGFR t790m-positive lung cancer;Mok;N Engl J Med,2017

4. Mechanisms of osimertinib resistance and emerging treatment options;Schmid;Lung Canc,2020

5. Emerging treatment paradigms for EGFR-mutant lung cancers progressing on osimertinib: a review;Piper-Vallillo;J Clin Oncol,2020

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Osimerinib haematological toxicities in non-small cell lung cancer: a randomised controlled trials meta-analysis;BMJ Supportive & Palliative Care;2024-08-19

2. Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancer;PLOS ONE;2024-05-16

3. Non-small cell lung cancer: an update on emerging EGFR-targeted therapies;Expert Opinion on Emerging Drugs;2024-04-02

4. PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: Clinical challenges and opportunities;Pharmacological Research;2024-04

5. Insights into the Overcoming EGFR^{Del19/T790M/C797S} Mutation: A Perspective on the 2‐Aryl‐4‐aminothienopyrimidine Backbone;ChemMedChem;2024-03-07